Search research articles
Contact Us
Filters
Showing results (11-20 of 60) with videos related to
Page
of 6
Sort By:
Journal of Evaluation in Clinical Practice
|
March 24, 2007
A centralized Pharmacy Unit for cytotoxic drugs in accordance with Italian legislation
Paolo Baldo, Antonella Bertola, Giancarlo Basaglia, et al.
Journal of Ovarian Research
|
October 21, 2014
Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study
Giorgio Giorda, Angiolo Gadducci, Emilio Lucia, et al.
Tumori
|
May 7, 2002
Idarubicin
Diana Crivellari, Giuseppe Toffoli, Davide Lombardi, et al.
Molecular Medicine Reports
|
June 21, 2011
'Genetic profiling' and ovarian cancer therapy (review)
Nadia Vella, Marco Aiello, Alessia Erika Russo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 5, 2010
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer
Viviana Murgia, Roberto Sorio, Claudia Griso, et al.
Tumori
|
August 12, 2003
Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases
Massimo Libra, Roberto Sorio, Angela Buonadonna, et al.
Tumori
|
August 19, 2004
Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study
Davide Lombardi, Diana Crivellari, Cristina Scuderi, et al.
Tumori
|
March 15, 2005
A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma
Carmela Arcuri, Roberto Sorio, Germana Tognon, et al.
Investigational New Drugs
|
October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer
Christian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
International Journal of Molecular Sciences
|
May 31, 2020
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
Michele Bartoletti, Giacomo Pelizzari, Lorenzo Gerratana, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 60) with videos related to
Sort By:
Page
of 6
Journal of Evaluation in Clinical Practice
|
March 24, 2007
A centralized Pharmacy Unit for cytotoxic drugs in accordance with Italian legislation
Paolo Baldo, Antonella Bertola, Giancarlo Basaglia, et al.
Journal of Ovarian Research
|
October 21, 2014
Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study
Giorgio Giorda, Angiolo Gadducci, Emilio Lucia, et al.
Tumori
|
May 7, 2002
Idarubicin
Diana Crivellari, Giuseppe Toffoli, Davide Lombardi, et al.
Molecular Medicine Reports
|
June 21, 2011
'Genetic profiling' and ovarian cancer therapy (review)
Nadia Vella, Marco Aiello, Alessia Erika Russo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 5, 2010
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer
Viviana Murgia, Roberto Sorio, Claudia Griso, et al.
Tumori
|
August 12, 2003
Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases
Massimo Libra, Roberto Sorio, Angela Buonadonna, et al.
Tumori
|
August 19, 2004
Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study
Davide Lombardi, Diana Crivellari, Cristina Scuderi, et al.
Tumori
|
March 15, 2005
A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma
Carmela Arcuri, Roberto Sorio, Germana Tognon, et al.
Investigational New Drugs
|
October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer
Christian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
International Journal of Molecular Sciences
|
May 31, 2020
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
Michele Bartoletti, Giacomo Pelizzari, Lorenzo Gerratana, et al.
Page
of 6